India’s Jubilant Organosys Nets $92 Million CRAMS Order For 2008
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - India's growing success in the pharmaceutical custom research and manufacturing services sector is demonstrated by Jubilant Organosys netting CRAMS contracts totaling $92 million for 2008, with most contracts coming from Japan, China, the U.S. and Europe, the Uttar Pradesh-based manufacturer said Feb. 2
You may also be interested in...
Jubilant Profits Spurred By Foreign Business
Buoyed chiefly by earnings from its foreign businesses, India's pharmaceuticals and chemicals major Jubilant Organosys reported a net profit of 4 billion rupees ($98 million) for the year ending March 31
Jubilant Profits Spurred By Foreign Business
Buoyed chiefly by earnings from its foreign businesses, India's pharmaceuticals and chemicals major Jubilant Organosys reported a net profit of 4 billion rupees ($98 million) for the year ending March 31
PharmAsia News India Pharma Roundup: Jubilant Organosys, Drug Price Cuts, Pharma Advisory Forum, Ranbaxy
NEW DELHI - India's Jubilant Organosys' $225 million all-cash deal for Canada's Draxis Health provides the company a path to consolidate contract manufacturing in North America with a contract in hand to launch a generic version of Johnson & Johnson's imaging agent Cardiolite in 2008 and time to mull whether to retain the company's currently high margin but increasingly competitive radiopharmaceutical business, Kotak Institutional Equities said